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Introduction: Acute kidney injury is a severe complication occurring in critically ill patients treated in the intensive care units, which has 
a significant impact on morbidity and mortality in these patients. Moreover, despite technological and pharmaceutical advances during 
the last decades, acute kidney injury is still associated with markedly increased morbidity and mortality. Creatinine, the most common 
renal dysfunction biomarker in use, has poor predictive accuracy for renal injury due to time delay in its increase and the influence by 
other factors on its serum concentration such as age, gender, muscle mass etc. Therefore, the need for better renal biomarkers in order 
to early detect and intervene for acute kidney injury prevention is imperative. During the last years several new acute kidney injury bi-
omarkers have been discovered and validated to improve early detection of patients in risk groups for progressive renal failure, need 
for renal replacement therapy or death.  
Aim: The purpose of the present article is to review the studies that have tested the predictive ability of those biomarkers (in urine 
and/or plasma) for early detection of acute kidney injury in the mixed adult intensive care unit population.   
Material and Method: We searched Medline (PubMed) using the keywords: acute kidney injury, biomarkers, renal failure, ICU. 
Results: The most relevant articles were included in this review. 
Conclusions: During the past decade, multiple AKI biomarkers have been studied and viewed as promising. Further studies are needed 
to determine their clinical utility.  
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INTRODUCTION 
Acute kidney injury (AKI) consists of a rapid renal function de-
cline or loss which usually increases serum urea and serum 
creatinine (sCr) levels, and induces uremic symptoms second-
ary to the accumulation of nitrogenous waste substances in the 
blood. AKI incidence varies from 1-7% of all hospitalized pa-
tients to 30-50% of intensive care unit (ICU) patients with 
13,5%  of them requiring renal replacement therapy (RRT). De-
spite many efforts to improve prevention and treatment, AKI is 
still associated with markedly increased morbidity, mortality 
and health care costs [1]. Because of the above-exposed rea-
sons, AKI early identification is crucial for its prompt treatment 
and a better prognosis. The purpose of the present article is to 
review the studies that have tested the prognostic ability of all 
novel renal biomarkers for early AKI development in a mixed 
population of adult critically ill patients during the past decade 
(excluding cardiac surgery patients). 
 
DIAGNOSIS OF AKI 
According to Kidney Disease Improving Global Outcomes 
(KDIGO) classification in 2012, AKI is diagnosed if sCr increases 
by 0,3mg/dl (26,5μmol/L) or more in 48h or rises to at least 
1.5-fold from baseline within 7 days. AKI stages are defined by 
the maximum change of either sCr or urine output (UO) 
(UO<5ml/kg/h x 6-12h, or UO< 3ml/kg/h x 24h or anuria x 
12h) [2]. As a result of recent standardization of diagnostic and 
staging criteria for AKI, our understanding of the epidemiology 
of AKI has improved in a variety of settings, including outpa-
tient clinics, emergency departments, patient wards and ICUs.  
 
Creatinine limitations 
sCr is a metabolite of creatine, a molecule that is synthesized 
from the amino acids glycine and arginine in liver, pancreas, 
and kidneys and that serves as a rapidly mobilizable reserve of 
high energy phosphates in skeletal muscles. Due to its low mo-
lecular weight (113 Da), creatinine is freely filtered by the glo-
meruli. In health, there is a constant production rate matching 
the rate of renal excretion [3].   
The role of creatinine as a marker of renal function is limited by 
the fact that its half life increases from 4h to 24-72h if the glo-
merular filtration rate (GFR) decreases. Thus, the serum con-
centration may take 24-36h to rise after a definite effect in 
renal function. Furthermore, a true fall in GFR may not be ade-
quately reflected by sCr in patients with sepsis, liver disease 
and /or muscle wasting. Drugs also affect sCr concentration, 
which compete with tubular secretion. In this case, sCr may 
fluctuate without change in renal function [3-4].  
Due to the fact that sCr is measured as a concentration, it is 
therefore affected by variation in volume status. As a result, the 
diagnosis of AKI may be delayed or missed in significant fluid 
shifts or fluid overload. A post-hoc analysis of the fluid and 
catheter management trial revealed that AKI was classified dif-
ferently in up to 18% of patients after sCr was adjusted for net 
fluid balance and estimated total body water. Affected patients 
had mortality rates similar to those with AKI that was present 
before the adjustment [4]. 
 In patients with normal kidney function, a rise in sCr by 0.3 
mg/dl may be due to an important reduction in GFR. On the 
contrary, in patients with underlying CKD, rises in sCr represent 
variable changes in GFR and a rise by 0.3 mg/dl may be within 
the acceptable daily variation and reflect an inconsequential 
change in GFR.  
Finally, single sCr values do not provide any information about 
specific stages of the AKI process. The most significant issue is 
that they do not indicate whether a patient is in a progression 
phase or if recovery has already begun. Also eGFR formulas are 
not valid to determine renal function in AKI [5]. 
 
Urine output limitations 
Oliguria is one of the oldest ''biomarkers'' of renal injury. Its 
association with AKI appeared more than 200 years ago as 
described by the English physician Heberden. However, the 
utility of oliguria as a predictor of AKI in hospitalized patients is 
limited by its relative sensitivity but poor specificity [6]. In fact, 
urine output may persist until renal function almost ceases. 
Therefore, the presence of oliguria may be misleading in that it 
may reflect a normal physiological response or may be indica-
tive of transient haemodynamic disturbance and not necessari-
ly indicative of significant tubular injury. Indeed, severe tubular 
injury may not be apparent initially as oliguria given that con-
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centrating ability is disturbed. Under such circumstances, urine 
flow reflects GFR and oliguria will not be apparent until GFR 
has fallen significantly [7]. The KDIGO criteria for AKI are based 
on the presence of oliguria for a minimum 6h [2]. Several ex-
perts used a longer minimum period of oliguria (e.g. 12h) in 
order to provide a significant prediction of the development of 
AKI [8]. Others have found a correlation between the volume of 
urinary output and the duration of oliguria and recommended 
a lower threshold for urinary output (e.g. 0.3 ml/ kg/h instead 
of 0.5 ml/kg/h) for the definition of stage of AKI [9].  
Given the increased risk for mortality associated with AKI, it is 
easy to understand why those patients who fulfill both urine 
output and sCr criteria for higher AKI stages do worse, sug-




A biomarker is defined as a structural, biochemical, physiologic 
or genetic parameter change, which indicates the presence, 
severity, or progress of a disease. Regarding kidney injury, it 
begins by inducing biological and molecular changes, which 
evolve to cellular damage and can be early detected by bi-
omarkers, since they represent the early stress response of the 
kidney tubules injury [10]. 
The 10th Acute Dialysis Quality Initiative (ADQI) Consensus 
Conference suggested  making use of both function and dam-
age biomarkers in combination with traditional markers of re-
nal function in order to define AKI [10]. The purpose was to 
transform the way clinicians diagnose and manage patients 
with AKI, by outlining its spectrum better than sCr and urine 
output alone. Several biomarkers of AKI in plasma or urine 
have been tested so far for their ability to predict AKI and need 
for RRT.   
The availability of these new markers has allowed the detection 
of subtle changes in renal function before sCr rises and the 
identification of evidenced kidney injury, without a change in 
sCr (sub-clinical AKI) [11]. It is worth mentioning that bi-
omarker positive, creatinine negative patients appear to have a 
greater risks of complications, longer hospital stay and higher 
mortality compared to patients without a biomarker rise. How-
ever in certain situations, these events reflect higher severity of 
illness rather than degree of AKI [10-11]. The main biomarkers 
are analyzed below. 
 
Neutrophil gelatinase - associated lipocalin (NGAL)  
NGAL is a novel 25-KDa protein expressed by neutrophils and 
various epithelial cells. It is a member of the lipocalin family of 
proteins, which transport small hydrophobic molecules like 
steroids, retinoids, and lipids. NGAL concentrations are elevat-
ed in the serum of patients with acute bacterial infections, 
which is consistent with NGAL's proposed function as an en-
dogenous bacteriostatic protein that scavenges bacterial sider-
ophores (small molecules which bind iron). By binding iron, 
NGAL could mediate various physiologic functions, such as 
bacteriostatic and antioxidant effects. Additionally, there are 
data supporting a role of NGAL as a growth factor, regulating 
apoptosis or cell differentiation and as a regulator of the epi-
thelial phenotype, inducing the formation of kidney epithelia in 
embryo and adults [12]. Mishra et al, initially proposed NGAL 
as an indicator for early renal injury secondary to renal hy-
poperfusion [13], and since then it has been studied in a variety 
of clinical contexts, both in children and adults. NGAL was 
found to be a useful early AKI predictor, operating its urine or 
serum levels equally well, having even prognostic value for 
initiation of dialysis and mortality. Comparing NGAL perfor-
mance with sCr-derived glomerular filtration rate (eGFR), serum 
NGAL (sNGAL) and urine NGAL (uNGAL) had diagnostic supe-
riority over sCr-based eGFR for predicting AKI. However, an 
increase in sNGAL generation does not seem specific to AKI, 
since it has been described in many pathologies such as chron-
ic obstructive disease (COPD), severe pancreatitis, inflammatory 
bowel disease, chronic renal disease, as well as in ICU patients 
without AKI [12].  
In a large prospective study of De Geus et al, 632 consecutive 
patients were included of whom 16% had AKI on entry. The 
percentage of patients with more severe AKI (RIFLE F) was 9%. 
The ROC-AUCs for AKI prediction 1 week after admission were 
0.77 for admission plasma NGAL (pNGAL) and 0.80 for admis-
sion uNGAL, while the AUCs for RRT need were 0.88 for admis-
sion pNGAL and 0.89 for admission uNGAL [14]. In another 
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study which included 528 patients, Pickering et al aimed to 
evaluate the ability of pNGAL to reflect both decreased filtra-
tion and structural injury. On ICU entry the AUCs for the diag-
nosis of Functional AKI (defined by changes in sCr) was 0.74 
and for Structural AKI (defined by elevations in uNGAL) was 
0.79 respectively. pNGAL predicted the need for dialysis (AUC: 
0.79), but not for death [15]. Hjortrup et al, in a prospective 
observational study concluded that in ICU patients with severe 
sepsis pNGAL and uNGAL had low predictive power for use of 
RRT, AKI and 90-day mortality. Two-hundred- twenty-two pa-
tients were included in the study. The AUCs for predicting use 
of RRT in ICU were 0.70 and 0.62 for pNGAL and uNGAL re-
spectively. Moreover, the AUCs of pNGAL and uNGAL for AKI 
were 0.66 and 0.71, and for 90- day mortality 0.55 and 0.61, 
respectively. Combining NGAL values with sCr did not improve 
the AUCs [16]. Linko et al, in a prospective multi-centre study in 
25 ICUs that included 369 patients, found that baseline pNGAL 
gives no additional value for prediction of hospital and 90-day 
mortality compared with severity scores (RIFLE or SAPS II) and 
has only moderate predictive power regarding RRT in critically 
ill adult patients with acute respiratory failure. The AUCs of 
baseline pNGAL were 0.73 for RRT, 0.62 for hospital and 0.58 
for 90-day mortality, respectively [17], [Table 1]. 
 
Cystatin C (CysC) 
CysC is a 13.3 kDa non-glycosylated cysteine protease inhibitor 
produced by all nucleated cells of the body, which is released 
into the intravascular compartment at a constant rate. CysC is 
freely filtered by the glomerulus, and subsequently reabsorbed 
by the renal proximal tubule through the endocytic receptor 
megalin and catabolized [12]. Unlike sCr, CysC is not secreted 
into the urine by the tubule, and it is not normally found in 
urine in significant amounts, although urinary CysC (uCys) ex-
cretion is increased by albuminuria. Consequently, serum cysta-
tine (sCysC) concentration is a marker of glomerular filtration 
rate (GFR), whereas urinary CysC (uCysC) can reflect tubular 
damage [18]. The blood concentration of CysC depends on the 
individual’s GFR, and the correlation between CysC and GFR is 
evident even in a range where sCr cannot detect changes, 
namely GFR of 60-90 mL/min; that means that sCr is insensitive 
for small decreases in GFR. In more severe renal impairment 
accompanied by a marked reduction of the GFR, CysC could 
not demonstrate any superiority over sCr. It is important to 
recognize that the analysis of CysC may be affected by thyroid 
dysfunction, cigarette smoking, inflammation, cancer, and glu-
cocorticoids but seems to be independent of gender, race, 
muscle mass, and hydration status [12, 18]. 
Nejat et al studied 444 critically ill patients. Based on the crite-
ria used by the AKIN definition, 28% of patients had AKI on 
entry, 16% developed AKI over the subsequent 7 days, and 
55% did not. Plasma CysC (pCyC) rose prior to sCr in 66% of 
patients developing AKI after entry. pCyC on entry was predic-
tive for sustained AKI (AUC:0.80), defined as an increase in sCr 
of at least 50% from baseline for 24h or longer, but not for AKI 
within 7 days (AUC:0.65) [19]. In a multicenter prospective 
study, Royakkers et al studied 151 ICU patients that were sepa-
rated in three groups:  Group 0 (N=60): non -AKI, group 1 
(N=35): AKI after admission, and group 2 (N=56): AKI at admis-
sion. They compared the two days prior to developing AKI 
from group 1 with the first two study days from group 0. The 
diagnostic performance for both pCysC (AUC: 0.72) and uCyC 
(AUC<0.50) was moderate 2 days prior to AKI diagnosis. More-
over, their prognostic ability for the need of RRT was poor 
(AUC < 0.66) [20]. In another prospective observational study, 
Pipili et al tested the diagnostic performance of a panel of 
novel biomarkers in mechanically ventilated critically ill pa-
tients. sCyC and sCr showed early maximum predictive ability 
within 10 days of ICU admission. sCyC combined with either 
normalized uNGAL or absolute uNGAL were best predictors for 
RRT initiation (AUC-ROC: 0.8) [21], [Table 2]. 
 
Kidney injury molecule -1 (KIM-1)   
Kidney injury molecule-1 (KIM-1) is a type I cell membrane 
glycoprotein containing a unique six cysteine immunoglobulin-
like domains and a mucin domain in its extracellular portion. 
ΚIM-1 is expressed at low levels in the normal kidney and also 
in other organs, but its expression is significantly upregulated 
in the kidney after kidney injury, as it was initially identified 
using representational difference analysis on kidneys, following 
ischemia/reperfusion injury. In preclinical and clinical studies, 
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urinary KIM-1 (uKIM-1) has been used as an early diagnostic 
indicator of kidney injury. Studies in adults suggested that 
uKIM-1 was significantly elevated in patients with clinical diag-
nosis of acute tubular necrosis, and predicted adverse clinical 
outcomes, including dialysis requirement and mortality [22]. 
In a large prospective study of 529 patients, Endre et al, found 
that the AUCs of uKIM-1 for AKI prediction within 48 h post-
admission, dialysis, and death prediction in 7 days, were 0.55, 
0.62, and 0.56, correspondingly [23]. Analyzing data from the 
same population, Nejat et al found that uKIM-1 levels were 
significantly increased in pre-renal AKI compared with patients 
with no-AKI [24]. Furthermore, Koyner et al also described a 
predictive preoperative power of KIM-1 in relation to the de-
velopment of stage 1 and stage 3 AKI. The preoperative KIM-1 
was significantly different in those who did and did not go on 
to develop stage 1 AKI; KIM-1 provided an AUC of 0.67, where-
as the KIM-1 early max performed even better (AUC: 0.69).  
KIM-1 was also useful for stage 3 AKI diagnosis with an AUC of 
0.82 [25], [Table 3].  
 
Interleukin-18 (IL-18) 
Interleukin-18, also known as interferon-gamma inducing fac-
tor, is a member of the IL-1 family of cytokines which regulates 
adaptive immunity. As an inactive 23-kDa percursor is synthe-
sized by several tissues including monocytes, macrophages, 
and proximal tubular epithelial cells, and is processed into an 
active 18,3 kDa cytokine by a caspase-1. IL-18 levels are en-
hanced in numerous endogenous inflammatory processes, 
such as sepsis, inflammatory arthritis, inflammatory bowel dis-
eases, systemic lupus erythematosus, psoriasis, hepatitis and 
multiple sclerosis, with this property significantly limiting its 
application due to low sensitivity and specificity. It is a sensitive 
mediator of ischemic injury in different organs (heart, brain, 
and kidney) [26]. IL-18 rises about 6h after the injury and peaks 
approximately 12h later at values up to 25 times of normal 
levels. During ischemic AKI, caspase-1 mediates conversion of 
pro-IL-18 to active IL-18, which is released from the tubular cell 
and mediates neutrophil infiltration into the renal parenchyma; 
thus IL-18 plays a deleterious role in AKI [12].  
Endre et al, evaluated IL-18 among other biomarkers (NGAL, 
CysC, KIM-1, GGT, AP) in a prospective observational study of 
523 ICU patients. The AUCs of uIL-18 for AKI diagnosis on entry 
and AKI prediction within 48h post-admission (in patients 
without AKI on entry) were 0.62 and 0.55 respectively. uIL-18 
predicted dialysis and death with an AUC of 0.73 and 0.68, cor-
respondingly. Performance was improved by stratification for 
eGFR or time or both. With eGFR<60 ml/min between 12 and 
36h of injury, uIL-18 had utility (AUC:0.94) [23]. According to 
Doi et al, the AUCs of uIL-18 for AKI prediction within 1 week 
after admission and prediction of death 14 days post-entry 
were 0.69 and 0.83, respectively [27]. In another study by Doi et 
al, uIL-18 in patients with pre-renal AKI showed modest but 
significantly higher concentrations that in patients with non-
AKI [28]. Finally, in a cohort study by Nisula et al, uIL-18 had 
poor to moderate ability to predict AKI (AUC: 0.58-0.66), RRT 
initiation (AUC: 0.65) and 90-day mortality in critically ill pa-
tients [29], [Table 4].  
 
Liver-type fatty acid- binding protein (L-FABP) 
L-FABP, also known as fatty acid-binding protein 1 (FABP-1), is 
a 14-kDa protein from the large superfamily of lipid-binding 
proteins. FABPs are small (15KDa) cytoplasmic proteins abun-
dantly expressed in all tissues with active fatty acid metabolism. 
Two types of FABPs have been identified in the human kidney: 
L-FABP in the proximal tubule and heart-type FABP (H-FABP) in 
the distal tubule. L-FABP binds selectively to free fatty acids 
(FFA), accomplishes the cellular uptake of fatty acids from 
plasma and regulates intracellular FFA metabolism [30]. L-FABP 
plays an important role as a cellular antioxidant during oxida-
tive stress, by maintaining low levels of FFAs in the cytoplasm 
of tubular cells through the facilitation of intracellular metabo-
lism and excretion in urine. Urinary liver fatty acid-binding pro-
tein (uL-FABP) is undetectable in healthy individuals, but under 
ischemic conditions, the tubular L-FABP gene expression is 
induced and in nephropathy, proximal tubular reabsorption of 
L-FABP is reduced [12]. 
In a prospective clinical study by Doi et al, 145 septic shock 
patients who were diagnosed as AKI at the time of ICU admis-
sion (established AKI) were analyzed. uL-FABP levels were sig-
nificantly higher in non-survivors than in survivors and a multi-
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ple logistic  regression analysis revealed that uL-FABP was sig-
nificantly associated with mortality. ROC curve analysis re-
vealed an AUC of 0.99 for death prediction [31]. Likewise, Doi 
et al found an AUC of 0.90 for 14-day mortality for uL-FABP 
measured on ICU admission. The AUC of uL-FABP for AKI pre-
diction 1 week post- ICU entry was 0.75 [27]. Finally, findings 
from a recent study showed that high uL-FABP-1 and uL-FABP-
3 levels could serve as markers for AKI patients with risk for 
dialysis need (p< 0.001) [32], [ Table 5].   
 
TIMP-2 and IGFBP7 
Tissue inhibitor of metalloproteinases 2 (TIMP-2) is 21-kDa 
protein, member of the TIMP family. TIMP-2 is an endogenous 
inhibitor of metalloproteinase activities. Insulin- like growth 
factor-binding protein 7 (IGFBP-7), a 29- kDa secreted protein, 
is known to bind and inhibit signaling via insulin-like growth 
factor 1 receptors. Both markers are involved in the process of 
G1 cell-cycle arrest that prevents cells from dividing in case of 
damage to the DNA until such damage can be repaired. TIMP-
2 and IGFBP-7 are markers of cellular stress in the early phase 
of tubular cell injury caused by a variety of insults (ischemia, 
oxidative stress, inflammation, drugs and toxins) [33]. 
[TIMP-2] X [IGFBP-7] was indicated as a fair to excellent bi-
omarker, in the ICU setting, in predicting moderate to severe 
AKI. In a landmark two stage multicenter study Kashani et al, 
tested the ability of 340 proteins, including known AKI bi-
omarkers, to predict development of AKI in an ICU population. 
TIMP-2 and IGFBP7 were validated in the second study-phase 
(Sapphire). In the final analysis cohort (heterogeneous sample 
of 728 critically ill patients) the two biomarkers were signifi-
cantly superior in order to forecast AKI stage 2 or 3. They 
demonstrated an AUC of 0.80 [34]. Furthermore, follow up 
studies using a cutoff value of 0.3 ng/ml for urinary [TIMP-2] X 
[IGFBP7], ascertained an AUC of 0.82 [35] and 0.79 [36] for the 
prediction of AKI stages 2 and 3 respectively. These findings 
indicated that, in the ICU setting [TIMP-2] X [IGFBP-7] is fair to 
excellent biomarker in predicting moderate to severe AKI with-
in 12h (mainly among those who are categorized at high risk 
for AKI).  In a long term follow-up study  Koyner et al,  showed 
that urinary  [TIMP-2] X [IGFBP7] levels  greater than 3.0 ng/ml  
were associated  with death or RRT requirement during the 
next 9 months in patients who developed AKI, [37] [Table 6]. 
 
Endogenous ouabain  
Endogenous ouabain (EO) is a neuroendocrine hormone syn-
thesized in the adrenal cortex. EO modulates the Na, K- ATPase 
pump activity and induces signal transduction via sodium-
calcium exchange and the Src-dependent pathway. The hyper-
tensive effect of EOis associated with organ damage and it is 
well established in both animal and human models. The mech-
anism of the EO effect is likely mediated by changes in cell 
Ca++ (activation of the Ca++-dependent protease calpain with 
an increase in nephrin protein cleavage or, via activation of the 
transcriptional regulator Snail with reduction in nephrin ex-
pression) [38]. 
In a study of Bignami et al, elevated preoperative EO levels 
were associated with a higher incidence of postoperative AKI 
(20.3 vs 2.8%, p<0.001) and ICU stay (2.4 +/- 0.59 vs. 1.4+/- 
0.38 days, p=0.014) [39]. In  another study of  Simonini et al, 
the preoperative  EO value was added to a different clinical AKI 
predictive model and resulted in a significant improvement of 
risk prediction power (AUC of AKI from 0.79 to 0.84 ; p < 
0.0001) [40],[Table 5].  
 
N-acetyl-β-glucosaminidase (NAG) 
NAG is a lysosomal enzyme mainly found in the proximal tu-
bule cells. Increased urinary concentration of NAG is a sensitive 
marker that may suggest renal injury. NAG enzyme is not fil-
trated by the glomerulus due to relatively high molecular 
weight (~ 140 kDa), but in active kidney disease urinary NAG 
(uNAG) levels are elevated. The utility of NAG still remains lim-
ited due to the fact that its urinary excretion is also elevated in 
chronic glomerular diseases [26].  
Doi et al, reported that in critically ill patients uNAG was a 
moderate predictor of both AKI within 1 week after admission 
(AUC: 0.62) and 14-day mortality (AUC: 0.66) [27]. Moreover, 
another study by Doi et al, found that patients with pre-renal 
AKI had higher concentrations of uNAG than patients with 
non-AKI [28], [Table 5]. 
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CONCLUSIONS 
AKI among critically ill patients is common worldwide and is 
associated with high morbidity, mortality, and prolonged hos-
pitalization. Timely identification of AKI and appropriate im-
plementation of preventive strategies are thought to be the 
most effective tools to improve AKI outcomes. During the past 
decade, multiple AKI biomarkers have been studied and viewed 
as promising, with the purpose of allowing clinicians to identify 
kidney injury earlier. So far, studies for NGAL have reported fair 
to moderate results for AKI prediction in the mixed ICU setting. 
[TIMP-2] X [IGFBP-] performed better in ICU patients that are 
categorized at high risk for AKI than any other reported bi-
omarker to date. Moreover, it is strongly suggested that bi-
omarkers be used in large randomized studies in order to vali-
date the role of each one of them (or a panel of them) in order 
to determine their clinical utility for earlier AKI diagnosis and 
improved risk assessment. 
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ANNEX 
     
TABLE 1.  Performance of NGAL in the mixed adult ICU. Studies with AUC-ROC analysis.  
 
 
┼: multicenter study; s: serum or plasma specimen, u: urine specimen; F: Functional-AKI = an increase in plasma creatinine or either > 
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┼: multicenter study; s: serum or plasma specimen; u: urine specimen; d: diagnosis of established AKI on admission; p: prediction of 
newly diagnosed AKI after ICU admission, in patients without AKI on entry; b: on day of AKI diagnosis; *:  2 days prior to AKI diagnosis 
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┼: multicenter study; d: diagnosis of established AKI on admission; p: prediction of newly diagnosed   AKI after ICU admission, in pa-
tients without AKI on entry; x: Pre-renal AKI vs no-AKI; y: AKI 48 vs no-AKI;  z: AKI 48 vs pre-renal AKI; I: stage I AKI; III: STAGE III AKI; NA: 
not available or not applicable. 
 
 







































































KDIGO 46.1 34.5 3 days Urine/ELISA 
kit  
58(54-62) 65(57-74) 53(49-57) 
┼: multicenter study; d: diagnosis of established AKI on admission; p: prediction of newly diagnosed  AKI after ICU admission, in patients without 
AKI on entry; t: total performance (d+p); NA:  not available or not applicable.   
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x: stage II, III AKI; d: diagnosis of established AKI on admission; p: prediction of newly diagnosed AKI after ICU admission, in patients 
without AKI; t: total performance, NA: not available or not applicable. 
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   79(69-88)   NA    NA 
┼: multicenter study; X: AKI stage 2 and 3; NA: not available or not applicable 
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